Technical Trend Overview and Price Movement
As of 5 March 2026, Hester Biosciences is trading at ₹1,499.75, down 2.69% from the previous close of ₹1,541.25. The stock’s intraday range has been relatively narrow, with a low of ₹1,489.70 and a high of ₹1,518.30. This price action reflects a continuation of the recent downward pressure, with the stock hovering closer to its 52-week low of ₹1,246.75 than its 52-week high of ₹2,347.70.
The technical trend has shifted from mildly bearish to bearish, indicating increased selling momentum. This shift is corroborated by the daily moving averages, which remain bearish, signalling that the short-term price action is under pressure. The bearish moving averages suggest that the stock is trading below key average price levels, which often acts as resistance in a downtrend.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, the MACD remains mildly bullish, hinting at some underlying positive momentum in the medium term. However, the monthly MACD is bearish, reflecting a longer-term weakening trend. This divergence between weekly and monthly MACD readings suggests that while short-term momentum may offer some relief rallies, the broader trend remains negative.
The KST (Know Sure Thing) indicator aligns with this view, showing mild bullishness on the weekly chart but bearishness on the monthly timeframe. This oscillation between timeframes highlights the stock’s struggle to sustain upward momentum over extended periods.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, indicating that the stock is neither overbought nor oversold. This neutral RSI suggests that the stock’s price momentum is balanced but vulnerable to directional shifts based on market catalysts.
Conversely, Bollinger Bands on both weekly and monthly charts are bearish, signalling increased volatility and downward pressure. The stock price is likely trading near or below the lower band, which often indicates a bearish trend continuation or heightened selling pressure.
Volume and Dow Theory Signals
On-Balance Volume (OBV) indicators show no clear trend on weekly or monthly charts, implying that volume is not confirming price movements decisively. This lack of volume confirmation can be a warning sign that price moves may lack conviction.
Dow Theory assessments reveal a mildly bearish weekly trend, while the monthly trend shows no definitive direction. This suggests that while short-term price action is weakening, the longer-term trend remains uncertain, requiring close monitoring for any breakout or breakdown signals.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- - Clear entry/exit targets
- - Target price revealed
- - Detailed report available
Comparative Returns and Market Context
When analysing Hester Biosciences’ returns relative to the broader market, the stock has underperformed the Sensex over most recent periods. Over the past week, the stock declined by 2.68%, while the Sensex fell 3.84%, indicating a slightly better relative performance in the very short term. Over one month, Hester Biosciences dropped 1.85%, outperforming the Sensex’s 5.61% decline. Year-to-date, the stock is down 5.79%, compared to the Sensex’s 7.16% fall.
However, over longer horizons, the stock’s performance is less favourable. Over one year, Hester Biosciences gained 6.00%, lagging behind the Sensex’s 8.39% rise. The three-year and five-year returns are notably negative at -13.81% and -12.35% respectively, while the Sensex posted robust gains of 32.28% and 55.60% over the same periods. Despite this, the ten-year return for Hester Biosciences is impressive at 257.34%, surpassing the Sensex’s 221.00%, reflecting strong long-term growth potential.
Mojo Score and Analyst Ratings
MarketsMOJO assigns Hester Biosciences a Mojo Score of 36.0, categorising it as a Sell. This represents an upgrade from the previous Strong Sell rating issued on 30 January 2026, signalling a slight improvement in the stock’s outlook. The Market Cap Grade stands at 4, indicating a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.
The downgrade in technical trend to bearish, combined with the current Mojo Grade, suggests that investors should exercise caution. The mixed signals from technical indicators imply that while some short-term rallies may occur, the prevailing momentum is negative and could lead to further price erosion if bearish conditions persist.
Outlook and Investor Considerations
Given the current technical landscape, Hester Biosciences appears to be in a consolidation phase with a bearish bias. The daily moving averages and Bollinger Bands indicate downward pressure, while the weekly MACD and KST offer only mild bullish hints that may not be sufficient to reverse the trend. The absence of strong volume confirmation further weakens the conviction behind any upward moves.
Investors should monitor key support levels near the 52-week low of ₹1,246.75 and watch for any sustained break above the daily moving averages to signal a potential trend reversal. Until then, the stock remains vulnerable to further declines, especially if broader market conditions deteriorate.
Holding Hester Biosciences Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary
Hester Biosciences Ltd’s technical parameters have shifted towards a bearish momentum, with daily moving averages and Bollinger Bands signalling increased selling pressure. While weekly MACD and KST indicators offer mild bullish signals, the monthly outlook remains negative, underscoring the stock’s vulnerability in the medium to long term. The Mojo Score upgrade from Strong Sell to Sell reflects a modest improvement but still advises caution.
Relative to the Sensex, the stock has underperformed over most periods except for the very long term, where it has delivered substantial gains. Investors should carefully weigh the mixed technical signals and consider broader market trends before initiating or adding to positions in Hester Biosciences.
Close monitoring of support levels and volume trends will be critical in the coming weeks to identify any meaningful shifts in momentum that could alter the current bearish bias.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
